Symphony Asset Management’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Symphony Asset Management’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,395	Closed	-$561K	–	403
2017 Q4	$561K	Sell	10,395 -306	-3%	-$16.7K	0.06%	245
2017 Q3	$611K	Sell	10,701 -1,761	-14%	-$103K	0.07%	239
2017 Q2	$750K	Sell	12,462 -1,275	-9%	-$72.6K	0.08%	217
2017 Q1	$748K	Buy	+13,737	New	+$677K	0.07%	236

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Symphony Asset Management's BIVV Position: Q1 2018 in Review

Symphony Asset Management sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 10,395 shares — an estimated $561K sold.

Symphony Asset Management first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $750K in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Symphony Asset Management reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Symphony Asset Management sold 10,395 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $561K.
Symphony Asset Management first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Symphony Asset Management's Bioverativ Inc. Common Stock position peaked at $750K in Q2 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Symphony Asset Management's 13F filing for Q1 2018, filed 11 May 2018.